NCT04803227View on ClinicalTrials.gov

Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19

PHASE1TerminatedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

March 11, 2021

Primary Completion Date

May 28, 2021

Study Completion Date

May 28, 2021

Conditions

Covid19

Interventions

DRUG

Emricasan

Emricasan 25 mg BID (days 1-14). Oral (capsule) administration.

OTHER

Placebo

Placebo BID \*days 1-14). Oral (capsule) administration.

Trial Locations (1)

11203

SUNY Downstate Health Sciences University, Brooklyn

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Histogen

INDUSTRY